1-13 of 13
Ahmad Awada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Eric Van Cutsem, Joelle Collignon, Rikke L. Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Dirk Arnold, Edita Baltruskeviciene, Per Pfeiffer, Jeffrey Yachnin, Susanne Magnusson, Camilla Rydberg Millrud, Annika Sanfridson, Nedjad Losic, Ignacio Garcia-Ribas, Dominique Tersago, Ahmad Awada
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5293–5303.
https://doi.org/10.1158/1078-0432.CCR-24-0645
Published: 02 December 2024
View article titled, Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Open the PDF for Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Tae Won Kim, Howard A. Burris, III, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Jr, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3452–3463.
https://doi.org/10.1158/1078-0432.CCR-21-4020
Published: 15 August 2022
View article titled, First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Open the PDF for First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2762–2770.
https://doi.org/10.1158/1078-0432.CCR-22-0696
Published: 01 July 2022
View article titled, Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Open the PDF for Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study in another window
Journal Articles

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3329–3338.
https://doi.org/10.1158/1078-0432.CCR-20-4131
Published: 15 June 2021
View article titled, Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Open the PDF for Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean-Francois Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jérôme Galon, Fabienne Hermitte, Ketil André Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson, Øystein Rekdal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2755–2763.
https://doi.org/10.1158/1078-0432.CCR-20-3435
Published: 15 May 2021
View article titled, Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Open the PDF for Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1582.
https://doi.org/10.1158/1078-0432.CCR-21-0193
Published: 01 March 2021
View article titled, Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer
Open the PDF for Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer in another window
Journal Articles

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Laura Garcia-Estevez, Lowell Hart, Ahmad Awada, Claudio Zamagni, Patrick G. Morris, Lee Schwartzberg, Stephen Chan, Ayca Gucalp, Laura Biganzoli, Joyce Steinberg, Lorenzo Sica, Maureen Trudeau, Denka Markova, Jamal Tarazi, Zhou Zhu, Thomas O'Brien, Catherine M. Kelly, Eric Winer, Denise A. Yardley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6149–6157.
https://doi.org/10.1158/1078-0432.CCR-20-1693
Published: 01 December 2020
View article titled, A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Open the PDF for A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (20): 5310–5319.
https://doi.org/10.1158/1078-0432.CCR-20-1764
Published: 15 October 2020
View article titled, A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Seock-Ah Im, Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3348–3357.
https://doi.org/10.1158/1078-0432.CCR-17-3059
Published: 15 July 2018
View article titled, Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Open the PDF for Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6411–6420.
https://doi.org/10.1158/1078-0432.CCR-17-0613
Published: 31 October 2017
View article titled, Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Open the PDF for Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Erica L. Mayer, Jean-Francois Baurain, Joseph Sparano, Lewis Strauss, Mario Campone, Pierre Fumoleau, Hope Rugo, Ahmad Awada, Oumar Sy, Antonio Llombart-Cussac
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6897–6904.
https://doi.org/10.1158/1078-0432.CCR-11-0070
Published: 31 October 2011
View article titled, A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer in another window
Journal Articles

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 144–151.
https://doi.org/10.1158/1078-0432.CCR-05-1571
Published: 05 January 2006
View article titled, Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Open the PDF for Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer in another window
Journal Articles

Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: A Pilot Study

Gilles Freyer, Philippe Hennebert, Ahmad Awada, Thierry Gil, Joseph Kerger, Jean Selleslags, Christiane Brassinne, Martine Piccart, Dominique de Valeriola
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (1): 95–102.
Published: 01 January 2002
View article titled, Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: <subtitle>A Pilot Study</subtitle>
Open the PDF for Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: <subtitle>A Pilot Study</subtitle> in another window